DocWire News Editors

DocwireNews

<p>Ibrutinib administration was associated with a number of severe cardiac events, results from a new analysis suggest.<p>&ldquo;Ibrutinib has revolutionized treatment for several B-cell <a href="https://www.docwirenews.com/docwire-pick/new-pancreatic-cancer-drug-shows-promise-in-clinical-trial/">malignancies</a>,&rdquo; the researchers wrote. &ldquo;However, a recent clinical trial where [it] was used in a front-line setting showed increased mortality during treatment compared with conventional chemotherapy. Cardiovascular toxicities were suspected as the culprit but not directly assessed in the study.&rdquo;</p><p>The paper authors sought to characterize cardiovascular adverse drug reactions associated with the commonly used therapy. Using the VigiBase (international pharmacovigilance database), the authors performed disproportionality analyses using reporting odds ratios and information component to assess possible associations between the drug, cardiovascular adverse drug reactions and deaths linked to those reactions. Information component compared observed and expected results, and used disproportionate Bayesian reporting to assess differences. The results were published in the <em><a href="http://www.onlinejacc.org/content/74/13/1667">Journal of the American College of Cardiology</a></em>.</p><p>According to the results, there were 303 ibrutinib-associated cardiovascular deaths. The drug was linked to higher reporting of supraventricular arrhythmias (P&lt;0.0001), central nervous system hemorrhagic events (P&lt;0.0001), heart failure (P&lt;0.0001), ventricular arrhythmias (P&lt;0.0001), conduction disorders (P&lt;0.0001), central nervous system ischemic events (P&lt;0.0001), and hypertension (P&lt;0.0001). According to the authors, cardiovascular adverse drug reactions &ldquo;often occurred after ibrutinib administration.&rdquo; The also pointed out that cardiovascular adverse drug reactions were associated with fatalities that were related to the conditions, from about 10% with supraventricular arrhythmias and ventricular arrhythmias to about 20% with central nervous system events, heart failure, and conduction disorders. The reported specifically that ibrutinib-linked supraventricular arrhythmias carry a particularly poor prognosis when central nervous system events occur concomitantly (28.8% deaths; 15 of 52 cases).</p><p>&ldquo;Severe and occasionally fatal cardiac events occur in patients exposed to ibrutinib,&rdquo; the authors wrote in their abstract. &ldquo;These events should be considered in patient care and in clinical trial designs.&rdquo;</p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">Important <a href="https://twitter.com/hashtag/cardiooncology?src=hash&amp;ref_src=twsrc%5Etfw">#cardiooncology</a> study indeed. Ibrutinib is a useful drug but we need to better understand it's CV toxicities outside the RCT setting. <a href="https://twitter.com/dineshpmcc1?ref_src=twsrc%5Etfw">@dineshpmcc1</a> <a href="https://twitter.com/DarrylLeong?ref_src=twsrc%5Etfw">@DarrylLeong</a> <a href="https://twitter.com/oscaar84?ref_src=twsrc%5Etfw">@oscaar84</a> <a href="https://t.co/SWqYCYRQXf">https://t.co/SWqYCYRQXf</a></p>
<p>&mdash; Husam Abdel-Qadir (@husam247) <a href="https://twitter.com/husam247/status/1176246598369763330?ref_src=twsrc%5Etfw">September 23, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">Important study &#8294;<a href="https://twitter.com/CardioOncology?ref_src=twsrc%5Etfw">@CardioOncology</a>&#8297; &mdash; Severe and occasionally fatal cardiac events occur in <a href="https://twitter.com/hashtag/Cancer?src=hash&amp;ref_src=twsrc%5Etfw">#Cancer</a> patients exposed to ibrutinib &#8294;&#8294;<a href="https://twitter.com/JACCJournals?ref_src=twsrc%5Etfw">@JACCJournals</a>&#8297;  <a href="https://t.co/cKxuDSBfqC">https://t.co/cKxuDSBfqC</a></p>
<p>&mdash; Jess Scott, PhD (@cardiac_fitness) <a href="https://twitter.com/cardiac_fitness/status/1176244539578888192?ref_src=twsrc%5Etfw">September 23, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">Some great <a href="https://twitter.com/hashtag/cardioonc?src=hash&amp;ref_src=twsrc%5Etfw">#cardioonc</a> representation in this week's <a href="https://twitter.com/JACCJournals?ref_src=twsrc%5Etfw">@JACCJournals</a>&ndash;See <a href="https://twitter.com/DrJESalem?ref_src=twsrc%5Etfw">@DrJESalem</a> <a href="https://twitter.com/CardioOncology?ref_src=twsrc%5Etfw">@CardioOncology</a> work in IDing CV Toxicities Assoc With Ibrutinib&ndash;it's not just atrial fibrillation. Great work! <a href="https://twitter.com/Dr_Mike_Fradley?ref_src=twsrc%5Etfw">@Dr_Mike_Fradley</a> <a href="https://twitter.com/onco_cardiology?ref_src=twsrc%5Etfw">@onco_cardiology</a> <a href="https://twitter.com/arjunkg?ref_src=twsrc%5Etfw">@arjunkg</a> <a href="https://twitter.com/PrevCardioOnc?ref_src=twsrc%5Etfw">@PrevCardioOnc</a>   <a href="https://t.co/48yUP06ecy">https://t.co/48yUP06ecy</a></p>
<p>&mdash; Eric H Yang, MD (@datsunian) <a href="https://twitter.com/datsunian/status/1176269047576461312?ref_src=twsrc%5Etfw">September 23, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">Important about cardiovascular toxicity from Ibrutinib, &rdquo;patients should still be treated but <a href="https://twitter.com/hashtag/cardiovascular?src=hash&amp;ref_src=twsrc%5Etfw">#cardiovascular</a> monitoring essential!&rdquo; <a href="https://twitter.com/hashtag/mantlecelllymphoma?src=hash&amp;ref_src=twsrc%5Etfw">#mantlecelllymphoma</a> <a href="https://twitter.com/hashtag/ibrutinib?src=hash&amp;ref_src=twsrc%5Etfw">#ibrutinib</a> <a href="https://t.co/zRrzVwpo4a">https://t.co/zRrzVwpo4a</a></p>
<p>&mdash; Ingrid Glimelius (@glimelius) <a href="https://twitter.com/glimelius/status/1176544263099863040?ref_src=twsrc%5Etfw">September 24, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><p>&nbsp;</p></p>


James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Jordana Jampel

Glycan-Targeting Novel Vaccine Shows Promise for Vast Virus Protection

Infectious Disease

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Latest News

Ibrutinib Linked with Adverse Cardiovascular Events: Analysis

Cardiology

Ibrutinib administration was associated with a number of severe cardiac events, results from a new analysis suggest. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe